-
Something wrong with this record ?
Polymorphous adenocarcinoma of the salivary glands: reappraisal and update
V. Vander Poorten, A. Triantafyllou, A. Skálová, G. Stenman, JA. Bishop, E. Hauben, JL. Hunt, H. Hellquist, S. Feys, R. De Bree, AA. Mäkitie, M. Quer, P. Strojan, O. Guntinas-Lichius, A. Rinaldo, A. Ferlito,
Language English Country Germany
Document type Journal Article, Review
- MeSH
- Adenocarcinoma pathology surgery therapy MeSH
- Humans MeSH
- Salivary Glands, Minor * MeSH
- Salivary Gland Neoplasms pathology therapy MeSH
- Prognosis MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Although relatively rare, polymorphous adenocarcinoma (PAC) is likely the second most common malignancy of the minor salivary glands (MiSG). The diagnosis is mainly based on an incisional biopsy. The optimal treatment comprises wide surgical excision, often with adjuvant radiotherapy. In general, PAC has a good prognosis. Previously, PAC was referred to as polymorphous low-grade adenocarcinoma (PLGA), but the new WHO classification of salivary gland tumours has also included under the PAC subheading, the so-called cribriform adenocarcinoma of minor salivary glands (CAMSG). This approach raised controversy, predominantly because of possible differences in clinical behaviour. For example, PLGA (PAC, classical variant) only rarely metastasizes, whereas CAMSG often shows metastases to the neck lymph nodes. Given the controversy, this review reappraises the definition, epidemiology, clinical presentation, diagnostic work-up, genetics, treatment modalities, and prognosis of PAC of the salivary glands with a particular focus on contrasting differences with CAMSG.
Department of Imaging and Pathology University Hospitals Leuven KU Leuven Leuven Belgium
Department of Pathology University of Arkansas for Medical Sciences Little Rock AR USA
Department of Pathology University of Texas Southwestern Medical Center Dallas TX USA
Department of Radiation Oncology Institute of Oncology Ljubljana Slovenia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000736
- 003
- CZ-PrNML
- 005
- 20190118111935.0
- 007
- ta
- 008
- 190107s2018 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00405-018-4985-5 $2 doi
- 035 __
- $a (PubMed)29761209
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Vander Poorten, Vincent $u Department of Oncology-Section Head and Neck Oncology, Otorhinolaryngology-Head and Neck Surgery and Leuven Cancer Institute, University Hospitals Leuven, KU Leuven, Leuven, Belgium. vincent.vanderpoorten@uzleuven.be. Multidisciplinary Salivary Gland Society, Geneva, Switzerland. vincent.vanderpoorten@uzleuven.be.
- 245 10
- $a Polymorphous adenocarcinoma of the salivary glands: reappraisal and update / $c V. Vander Poorten, A. Triantafyllou, A. Skálová, G. Stenman, JA. Bishop, E. Hauben, JL. Hunt, H. Hellquist, S. Feys, R. De Bree, AA. Mäkitie, M. Quer, P. Strojan, O. Guntinas-Lichius, A. Rinaldo, A. Ferlito,
- 520 9_
- $a Although relatively rare, polymorphous adenocarcinoma (PAC) is likely the second most common malignancy of the minor salivary glands (MiSG). The diagnosis is mainly based on an incisional biopsy. The optimal treatment comprises wide surgical excision, often with adjuvant radiotherapy. In general, PAC has a good prognosis. Previously, PAC was referred to as polymorphous low-grade adenocarcinoma (PLGA), but the new WHO classification of salivary gland tumours has also included under the PAC subheading, the so-called cribriform adenocarcinoma of minor salivary glands (CAMSG). This approach raised controversy, predominantly because of possible differences in clinical behaviour. For example, PLGA (PAC, classical variant) only rarely metastasizes, whereas CAMSG often shows metastases to the neck lymph nodes. Given the controversy, this review reappraises the definition, epidemiology, clinical presentation, diagnostic work-up, genetics, treatment modalities, and prognosis of PAC of the salivary glands with a particular focus on contrasting differences with CAMSG.
- 650 _2
- $a adenokarcinom $x patologie $x chirurgie $x terapie $7 D000230
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a nádory slinných žláz $x patologie $x terapie $7 D012468
- 650 12
- $a malé slinné žlázy $7 D012470
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Triantafyllou, Asterios $u School of Dentistry, University of Liverpool, Liverpool, UK. Pathology Department, Liverpool Clinical Laboratories, Liverpool, UK.
- 700 1_
- $a Skálová, Alena $u Multidisciplinary Salivary Gland Society, Geneva, Switzerland. Department of Pathology, Charles University, Faculty of Medicine in Plzen, Plzen, Czech Republic.
- 700 1_
- $a Stenman, Göran $u Multidisciplinary Salivary Gland Society, Geneva, Switzerland. Department of Pathology and Genetics, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.
- 700 1_
- $a Bishop, Justin A $u Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- 700 1_
- $a Hauben, Esther $u Department of Imaging and Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
- 700 1_
- $a Hunt, Jennifer L $u Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
- 700 1_
- $a Hellquist, Henrik $u Epigenetics and Human Disease Laboratory, CBMR, Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.
- 700 1_
- $a Feys, Simon $u Department of Oncology-Section Head and Neck Oncology, Otorhinolaryngology-Head and Neck Surgery and Leuven Cancer Institute, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
- 700 1_
- $a De Bree, Remco $u Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
- 700 1_
- $a Mäkitie, Antti A $u Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
- 700 1_
- $a Quer, Miquel $u Multidisciplinary Salivary Gland Society, Geneva, Switzerland. Department of Otolaryngology, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
- 700 1_
- $a Strojan, Primož $u Department of Radiation Oncology, Institute of Oncology, Ljubljana, Slovenia.
- 700 1_
- $a Guntinas-Lichius, Orlando $u Multidisciplinary Salivary Gland Society, Geneva, Switzerland. Department of Otorhinolaryngology, Institute of Phoniatry/Pedaudiology, Jena University Hospital, Jena, Germany.
- 700 1_
- $a Rinaldo, Alessandra $u University of Udine School of Medicine, Udine, Italy.
- 700 1_
- $a Ferlito, Alfio $u International Head and Neck Scientific Group, Padua, Italy.
- 773 0_
- $w MED00009617 $t European archives of oto-rhino-laryngology official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery $x 1434-4726 $g Roč. 275, č. 7 (2018), s. 1681-1695
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29761209 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190118112150 $b ABA008
- 999 __
- $a ok $b bmc $g 1364752 $s 1038859
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 275 $c 7 $d 1681-1695 $e 20180514 $i 1434-4726 $m European archives of oto-rhino-laryngology $n Eur Arch Otorhinolaryngol $x MED00009617
- LZP __
- $a Pubmed-20190107
